Nephrotic Syndrome – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Nephrotic Syndrome – Pipeline Review, H2 2017’, provides an overview of the Nephrotic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome

The report reviews pipeline therapeutics for Nephrotic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Nephrotic Syndrome therapeutics and enlists all their major and minor projects

The report assesses Nephrotic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Nephrotic Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Nephrotic Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nephrotic Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Asahi Kasei Pharma Corp

Aurinia Pharmaceuticals Inc

Bristol-Myers Squibb Co

Orbis Biosciences Inc

Pfizer Inc

Retrophin Inc

Sarfez Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Nephrotic Syndrome - Overview 6

Nephrotic Syndrome - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Nephrotic Syndrome - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Nephrotic Syndrome - Companies Involved in Therapeutics Development 20

AbbVie Inc 20

Asahi Kasei Pharma Corp 20

Aurinia Pharmaceuticals Inc 21

Bristol-Myers Squibb Co 21

Orbis Biosciences Inc 22

Pfizer Inc 22

Retrophin Inc 22

Sarfez Pharmaceuticals Inc 23

Nephrotic Syndrome - Drug Profiles 24

abatacept - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

atrasentan hydrochloride - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

cosyntropin - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Fusion Proteins to Inhibit Complement C3 for Nephrosis - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

mizoribine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PF-06730512 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

prednisone - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

SP-20104 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

voclosporin - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Nephrotic Syndrome - Dormant Projects 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Number of Products under Development for Nephrotic Syndrome, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Nephrotic Syndrome – Pipeline by AbbVie Inc, H2 2017 20

Nephrotic Syndrome – Pipeline by Asahi Kasei Pharma Corp, H2 2017 20

Nephrotic Syndrome – Pipeline by Aurinia Pharmaceuticals Inc, H2 2017 21

Nephrotic Syndrome – Pipeline by Bristol-Myers Squibb Co, H2 2017 21

Nephrotic Syndrome – Pipeline by Orbis Biosciences Inc, H2 2017 22

Nephrotic Syndrome – Pipeline by Pfizer Inc, H2 2017 22

Nephrotic Syndrome – Pipeline by Retrophin Inc, H2 2017 23

Nephrotic Syndrome – Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 23

Nephrotic Syndrome – Dormant Projects, H2 2017 53

List of Figures

List of Figures

Number of Products under Development for Nephrotic Syndrome, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Top 10 Targets, H2 2017 12

Number of Products by Stage and Top 10 Targets, H2 2017 12

Number of Products by Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports